ANIK vs EOLS
ANIK: Anika Therapeutics manufactures and markets hyaluronic acid (HA)-based medical products for orthopedic pain management, tissue regeneration, and non-orthopedic surgical applications. EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.
Side-by-side fundamentals
| Metric | ANIK | EOLS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.01 | $5.89 | |
| Market cap as of 2026-07-23 | $199M | $379M | |
| Net margin as of 2026-07-23 | -9.5% | -14.4% | ANIK higher |
| Gross margin as of 2026-07-23 | +58.6% | +66.1% | EOLS higher |
| Operating margin as of 2026-07-23 | -10.5% | -8.1% | EOLS higher |
| ROE as of 2026-07-23 | -7.7% | -410.2% | ANIK higher |
| ROA as of 2026-07-23 | -5.9% | -19.4% | ANIK higher |
| Debt / equity as of 2026-07-23 | 0.00 | 22.00 | ANIK lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.4% | +9.6% | EOLS higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +26.0% | EOLS higher |
| Beta as of 2026-07-23 | 0.22 | 1.39 | |
| 1-year return as of 2026-07-22 close | +41.8% | -37.0% | ANIK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.